Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: 12 | Rare Historical Photos

DNA Sequencing Firm Illumina Sees Strong Clinical Market Momentum, Stock Soars

Illumina Inc. (NASDAQ:ILMN) stock is trading higher after the company reported better-than-expected third-quarter earnings.

Benzinga · Oct 31, 2025

AbbVie Raises 2025 Outlook Helped By Strong Immunology Growth, Boost Dividend

AbbVie Inc. (NYSE:ABBV) reported third-quarter 2025 sales of $15.78 billion on Friday, beating the consensus of $15.59 billion.

Benzinga · Oct 31, 2025

Baxter Trims Annual Outlook Again, Stock Hits 52-Week

Baxter International Inc. (NYSE:BAX) stock hit a 52-week low on Thursday, after the company again lowered its 2025 guidance.

Benzinga · Oct 30, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly and Co. (NYSE:LLY) on Thursday reported better-than-expected third-quarter earnings and boosted its annual forecast, sending the stock higher.

Benzinga · Oct 30, 2025

New Walmart Partnership to Let Patients Buy Eli Lilly's Zepbound Without Insurance Hassles

Eli Lilly partners with Walmart to sell its weight-loss drug Zepbound nationwide, giving patients easier, insurance-free access through LillyDirect.

International Business Times · Oct 30, 2025

‘Patients will suffer’: tales from the frontline of the UK pharma crisis

The pricing standoff between government and industry has stalled research and put thousands of jobs at risk

The Guardian - UK · Oct 30, 2025

Federal health officials push effort to spur cheaper biotech drugs

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend on to treat autoimmune diseases or cancers

The Independent UK · Oct 29, 2025

Read news from The Economist, FT, and more,
with one subscription

UK must reform drug pricing to become life sciences superpower, says GSK boss

Shares jump on higher profits as Emma Walmsley is ‘hopeful’ standoff with NHS can be resolved

The Guardian - UK · Oct 29, 2025

GSK Upgrades 2025 Financial Outlook, CEO Says Positioned Well For 2026

British pharmaceutical giant GSK Plc (NYSE:GSK) on Wednesday reported upbeat third-quarter results and upgraded its full-year 2025 guidance.

Benzinga · Oct 29, 2025

Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms

Incyte Corporation's (NASDAQ:INCY) third-quarter revenue was $1.37 billion. The company beat the consensus of $1.26 billion.

Benzinga · Oct 28, 2025

Novartis Maintains Outlook Even As Generics Bite Into Profits

Swiss pharmaceutical major Novartis AG (NYSE:NVS) reported third-quarter 2025 results on Tuesday, reaffirming its full-year guidance as strong sales from key growth drugs offset mounting generic competition in the U.S.

Benzinga · Oct 28, 2025

CSL share price plummets amid shareholder revolt over executive pay plans

US vaccination forecast leads to fall in stock price, while board survives spill in ‘second strike’ over pay concerns at AGM

The Guardian - AU · Oct 28, 2025

Avidity Biosciences Soars After $72 Per Share Novartis Takeover

Avidity Biosciences, Inc. (NASDAQ:RNA) stock surged after announcing a $12 billion all-cash acquisition by Novartis AG (NYSE:NVS), marking one of the largest biotech buyouts of the year.

Benzinga · Oct 27, 2025

Janus Henderson, Avidity Biosciences, BridgeBio Pharma And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Monday.

Benzinga · Oct 27, 2025

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Oct 27, 2025

EXCLUSIVE: Co-Diagnostics Inks JV With Saudi Arabia Firm For Middle East Market

Co-Diagnostics, Inc. (NASDAQ:CODX) announced on Monday that it has entered into a joint venture agreement with the Kingdom of Saudi Arabia (KSA) based Arabian Eagle Manufacturing.

Benzinga · Oct 27, 2025

Avidity Shareholders Win Big As Novartis Moves Fast On $12 Billion Deal

Avidity Biosciences, Inc. (NASDAQ:RNA) shares are rocketing premarket on Monday. On Sunday, the company agreed to merge with Novartis AG (NYSE:NVS) in a deal valued at $12 billion on a fully diluted basis.

Benzinga · Oct 27, 2025

Why Avidity Biosciences Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

Shares of Avidity Biosciences Inc (NASDAQ:RNA) rose sharply in pre-market trading after the company agreed to be acquired by Novartis AG (NYSE:NVS).

Benzinga · Oct 24, 2025

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Oct 24, 2025

Eli Lilly Bets Big On Eye Gene Therapy That Could End Repeat Injections

Eli Lilly and Company (NYSE:LLY) and Adverum Biotechnologies, Inc. (NASDAQ:ADVM) on Friday announced that they have entered into a definitive agreement under which Lilly will acquire Adverum Biotechnologies, including its lead product, Ixo-vec.

Benzinga · Oct 24, 2025

Mounjaro Maker Eli Lilly Jumps In Quality Despite Trump-Fueled Price Cut Fears

Eli Lilly and Co. (NYSE:LLY) has surged into the top decile of quality rankings among SP 500 peers, achieving a percentile score of 90.25 on the latest composite quality report, despite fresh uncertainty surrounding the future pricing of its blockbuster weight loss drug, Mounjaro.

Benzinga · Oct 23, 2025

Options Corner: A Reliable Quant Signal Just Flashed Again For Pharma Giant Novo Nordisk

At first glance, Novo Nordisk (NYSE:NVO) doesn't appear at all enticing. Down roughly 11% in the trailing month, NVO stock has been a victim of broader market pressure. But it's also the red ink that makes the pharmaceutical giant an enticing opportunity for options traders.

Benzinga · Oct 23, 2025

Scienture Holdings Stock Is Soaring Thursday: What's Fueling The Momentum?

Shares of Scienture Holdings, Inc. (NASDAQ:SCNX) are rising Thursday after the comprehensive pharmaceutical product company announced the start of commercial sales for Arbli.

Benzinga · Oct 23, 2025

Why Is Viking Therapeutics Stock Rising Today?

Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) are rising Thursday. The clinical-stage biopharmaceutical company reported third-quarter earnings and provided updates on clinical trials.

Benzinga · Oct 22, 2025

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.

Benzinga · Oct 22, 2025

Thermo Fisher's Upbeat Earnings Suggest Worst Is Over For Scientific Tools Sector, Analyst Says

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported third-quarter 2025 adjusted earnings of $5.79 per share, beating the street view of $5.49.

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

the Kingdom of Saudi Arabia

20 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.